SCHEMBL4424044

SCHEMBL4424044

CCN(Cc1ccc(O)cc1)c1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.75
ESRRG P62508 1/20 0.59
CNR2 P34972 4/20 0.58
CYP19A1 P11511 1/20 0.53
NR1H2 P55055 1/20 0.53
NR1H3 Q13133 1/20 0.53
ALDH1A1 P00352 3/20 0.49
ALDH2 P05091 1/20 0.49
LTB4R2 Q9NPC1 1/20 0.48
KDM4E B2RXH2 1/20 0.48
MITF O75030 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
RAD52 P43351 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
BCHE P06276 1/20 0.48
ACHE P22303 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27732459 0.98 TSHR (0.72) TSHRESRRGCNR2CYP19A1NR1H2
SCHEMBL10702263 0.93 TSHR (0.75) TSHRESRRGCNR2NR1H2NR1H3
SCHEMBL4407628 0.90 TSHR (0.91) TSHRESRRGCNR2NR1H2NR1H3
SCHEMBL8975208 0.88 TSHR (0.55) TSHRESRRGCNR2CYP19A1NR1H2
SCHEMBL179996 0.86 TSHR (1.00) TSHRESRRGCNR2NR1H2NR1H3
SCHEMBL20119625 0.85 TSHR (0.81) TSHRESRRGCNR2NR1H2NR1H3
SCHEMBL4400867 0.85 TSHR (0.81) TSHRESRRGCNR2NR1H2NR1H3
Hydrochloric Acid SCHEMBL3672654 0.84 TSHR (0.96) TSHRESRRGCNR2NR1H2NR1H3
Bromide SCHEMBL27967621 0.84 TSHR (0.96) TSHRESRRGCNR2NR1H2NR1H3
SCHEMBL11725374 0.83 TSHR (0.78) TSHRCNR2NR1H2NR1H3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0812827-B1 Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation SUMITOMO CHEMICAL CO (JP) 2009-09-02 EP disclosed
US-6815548-B2 MINTERMEDIATE FOR PHARMACEUTICALS SUCH AS PAROXETINE USEFUL AS ANTIDEPRESSANTS, REPRESENTED BY THE GENERAL FORMULA (I): SUMIKA FINE CHEMICALS CO., LTD. (JP) 2004-11-09 US disclosed
US-6730803-B2 PRODUCTION METHOD OF A BETA -KETO ESTER COMPOUND OF CLAIM 1, WHICH COMPRISES CONDENSATION OF A 2-CYANO-2,2-DIMETHYLACETATE SOLUTION TO GIVE 2-CYANO-2,2- DIMETHYLACETATE OF THE FORMULA (II), AND CONDENSATION THEREOF SUMIKA FINE CHEMICALS CO., LTD. (JP) 2004-05-04 US disclosed
EP-1394160-A1 Process for preparing crystalline paroxetin hydrochloride SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2004-03-03 EP disclosed
EP-1384720-A1 Process for drying paroxetine hydrochloride SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2004-01-28 EP disclosed
EP-1384711-A1 Optical resolution of a piperidine derivative SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2004-01-28 EP disclosed
US-6610851-B1 1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-((3,4-methylene dioxyphenyl)oxymethyl)piperidine; reacting 4-(4-fluorophenyl)-3-hydroxymethylpiperidine with di-tert-butyl dicarbonate to form the carbamate; 3,4-methylenedioxyphenol SUMIKA FINE CHEMICALS CO., LTD. (JP) 2003-08-26 US disclosed
US-20030144519-A1 Process for preparing a piperidine derivative SUMIKA FINE CHEMICALS CO., LTD. 2003-07-31 US disclosed
US-20030144533-A1 Synthetic intermediate for epothilone derivative and production method thereof SUMIKA FINE CHEMICALS CO., LTD. (JP) 2003-07-31 US disclosed
US-6476227-B1 Piperidine derivative and process for preparing the same SUMIKA FINE CHEMICALS CO., LTD. (JP) 2002-11-05 US disclosed
US-5948914-A PREPARING 4-(4-FLUOROPHENYL)-3-HYDROXYMETHYLPIPERIDINE BY OPTICALLY RESOLVING WITH O-CHLOROTARTRANILIC ACID; CHEMICAL INTERMEDIATE FOR DRUGS SUMIKA FINE CHEMICALS CO., LTD. (JP) 1999-09-07 US disclosed
EP-0812827-A1 Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1997-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144519-A1 Process for preparing a piperidine derivative TPH1, TPH2, HTR7 TSHR 681/4885ESRRG 2158/4885CNR2 333/4885
US-20030144533-A1 Synthetic intermediate for epothilone derivative and production method thereof HSD11B1, HSD17B7, HSD17B1 TSHR 2086/4885ESRRG 1147/4885CNR2 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.